Hot Features
프리미엄
Zenas BioPharma Inc (ZBIO)
NASDAQ
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout t... Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout the biopharmaceutical industry to identify, acquire and develop product candidates that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Our lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We are developing obexelimab for patients in several autoimmune diseases. 더 보기
-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy...
-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas...
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in...
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the...
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the...
ProShares, a premier provider of ETFs, announced today forward and reverse share splits on 20 of its ETFs. The splits will not change the total value of a shareholder's investment...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.3 | -14.2076502732 | 9.15 | 9.15 | 7.495 | 150704 | 8.04443536 | CS |
| 4 | -1.78 | -18.4839044652 | 9.63 | 10.95 | 7.495 | 402504 | 9.5757277 | CS |
| 12 | -15.54 | -66.4386489953 | 23.39 | 23.96 | 7.495 | 318797 | 11.22354561 | CS |
| 26 | -2.1704 | -21.6598139795 | 10.0204 | 26.11 | 7.495 | 186360 | 13.14382616 | CS |
| 52 | -2.1704 | -21.6598139795 | 10.0204 | 26.11 | 7.495 | 93920 | 13.14382616 | CS |
| 156 | -2.1704 | -21.6598139795 | 10.0204 | 26.11 | 7.495 | 31431 | 13.14382616 | CS |
| 260 | -0.87 | -9.97706422018 | 8.72 | 26.11 | 7.495 | 22479 | 12.97404995 | CS |
misterfishman
45 초 전
Wayne R
54 초 전
Seminole Red
6 분 전
eagle8
10 분 전
Ribo
19 분 전
sab63090
22 분 전
Seminole Red
31 분 전
beacham
33 분 전
diggitydoodle
37 분 전
SkeBallLarry
41 분 전
Seminole Red
42 분 전
SkeBallLarry
42 분 전
SkeBallLarry
43 분 전
Big Benny
43 분 전
sab63090
44 분 전
SkeBallLarry
44 분 전
SkeBallLarry
46 분 전
Slyhunter
46 분 전
rocketeer357
46 분 전
rocketeer357
51 분 전
Jp_SHMP
52 분 전
Methinks
54 분 전
sab63090
54 분 전
SREZ
54 분 전
